A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)

NCT02593760 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis

Interventions

OTHER: Placebo
DRUG: Ruxolitinib
DRUG: Vismodegib

Sponsor

Hoffmann-La Roche